Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative chemo-immunotherapy for resectable colorectal peritoneal metastases
NL-OMON60093Phase 3Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) and peritoneal carcinomatosis (PC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Overall survival, Feasibility of accrual and 1 more. Started Aug 2026; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON60093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60093.